Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
A single missed dose has minimal impact on overall results
AOD-9604 + CJC-1295 + Ipamorelin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use
8 weeks 56 syringes 1 syringe per day across 8 weeks
FDA's 2024 review states the mechanism of action is still unknown, which limits how confidently any specific physiological effect can be predicted in humans
Related Resources Explore additional peptide therapy resources to optimize your metabolic health journey: Semaglutide GLP-1 receptor agonist for appetite control and glucose regulation Tirzepatide Dual GIP/GLP-1 agonist for enhanced metabolic support CJC-1295/Ipamorelin Growth hormone secretagogue for muscle preservation and recovery Tesamorelin GHRH analog targeting visceral adipose tissue reduction Schedule a Peptide Therapy Consultation Discuss your metabolic optimization goals with our medical team
US$ 20.55
US$ 28.16
US$ 26.59
US$ 25.82
US$ 20.84
